$CVAC News

Last published 2mo ago

2mo agoCVACBarclays 19th Annual Global Consumer Conference - CUREVAC NVEarnings Call Transcriptsso delighted to welcome buyer consumer health to the back to school conference welcome guys i'm going to try and make this five-way conversation work let's see if we can figure this out so i want to introduce the team ju
10mo agoBMY BNTX CVACBioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA FieldGlobeNewswireBioNTech has completed its exchange offer to acquire CureVacAcquisition complements BioNTech's capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturingIn total,
11mo agoBNTX CVACBioNTech Achieves Minimum Condition in CureVac Exchange OfferGlobeNewswireThe minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expiration of the initial
11mo agoBNTX CVACBioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time ExpirationGlobeNewswireOffer set to expire at 9:00 am Eastern Time on December 3, 2025, with CureVac shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2025, due to operational deadlines.Exchange ratio of
11mo agoCVACCureVac Announces Voting Results of Extraordinary General MeetingACCESS NewswireTÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. , a pioneering multinational biotech company developing a new class of transformative medicines
11mo agoCVACCureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business UpdatesACCESS NewswireGerman Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an important step toward the expected closing later this yearOffer period for BioNTech's
1y agoBNTX CVACBioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.GlobeNewswireAcquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next milestone in the execution of its oncology
1y agoCVACCureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesACCESS NewswireCureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesEntered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all shares of
1y agoCVACCureVac Announces Voting Results of General MeetingACCESS NewswireTÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. , a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA
1y agoBNTX CVACBioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange OfferGlobeNewswireAcquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next key milestone in the execution of its oncology strategy
1y agoCVACCureVac Announces Financial Results for the First Quarter of 2025 and Provides Business UpdatesACCESS NewswireU.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer , with clinical study expected to begin H2 2025; Clinical Trial Application filed in
1y agoCVACCureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SEACCESS NewswireEuropean Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendments to specific patent
1y agoCVACCureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business UpdateACCESS NewswireStrategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate TransformationCompleted enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy
1y agoCVACCureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025ACCESS NewswireTÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. , a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid
1y agoCVACCureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung CancerACCESS NewswireSignificant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancerProprietary Epitopes: CVHNLC encodes novel tumor epitopes
1y agoCVACCureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SEACCESS NewswireEuropean Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended formA hearing on infringement of EP 3 708 668 B1 is
1y agoCVACCureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top InnovatorsACCESS NewswireCureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolioThe company holds one of the broadest
1y agoCVACCureVac N.V. (CVAC) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
1y agoCVACCureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business UpdateACCESS NewswireStrengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to
2y agoCVACCureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024ACCESS NewswireTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. , a global biopharmaceutical company developing a new class of transformative medicines based on
2y agoCVACCureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial OfficerACCESS NewswireExperienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V.
2y agoCVACCureVac to Present at the 12th International mRNA Health ConferenceACCESS NewswireTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. , a global biopharmaceutical company developing a new class of transformative medicines based on
2y agoCVACCureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingACCESS NewswireTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. , a global biopharmaceutical company developing a new class of transformative medicines based on
2y agoCVACCureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 CongressACCESS NewswirePreliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune responses were de novo, observed in patients
2y agoCVACCureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine ProgramACCESS NewswirePhase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpointsVaccine candidate based on CureVac's proprietary
2y agoCVACCureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 CongressACCESS NewswireTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 / CureVac N.V. , a global biopharmaceutical company developing a new class of transformative medicines based on
2y agoCVACCureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business UpdateACCESS NewswireClosed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platformInitiated strategic workforce reduction of ~30% by end
2y agoCVACCureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected GlioblastomaACCESS NewswireFirst patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBMPart B expected to include up to 20 patients to generate extended data on safety,
2y agoCVACCureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory BoardACCESS NewswireTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. , a global biopharmaceutical company developing a new class of transformative medicines based on
2y agoCVACCureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTechACCESS NewswireNew trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas TherapeuticsFirst instance decision on validity of EP 3 708 668 B1 scheduled for March 25,
2y agoCVACAgomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial OfficerBusiness WireAgomab Therapeutics NV (‘Agomab') today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more than 15 years of experience in global biotech
2y agoCVACCureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline OpportunitiesACCESS NewswireStrategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organizationPrioritization of high-value opportunities in
2y agoCVAC GSKGSK and CureVac to Restructure Collaboration into New Licensing AgreementACCESS NewswireGSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional
2y agoCVACCureVac Announces Voting Results of General MeetingACCESS NewswireTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 24, 2024 / CureVac N.V. , a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger
2y agoCVACCureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSKACCESS NewswirePhase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strainStudy initiated following previously reported interim data from Phase 2 Part of
2y agoCVACCureVac Announces Financial Results for the First Quarter of 2024 and Provides Business UpdateACCESS NewswireOrganizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year endU.S. FDA Fast Track designation granted for pre-pandemic avian influenza vaccine currently in Phase
2y agoCVACCureVac N.V. (CVAC) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
2y agoCVACCureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business UpdateACCESS NewswireOrganizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costsTogether with GSK, ended Pandemic Preparedness Agreement with Federal
2y agoCVACCureVac Appoints Thaminda Ramanayake as New Chief Business OfficerACCESS NewswireMr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-makingStrong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing
2y agoCVACCureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSKACCESS NewswirePhase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza virus, considered to be potential future pandemic threatStudy will assess monovalent
2y agoCVACCureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer VaccinesACCESS NewswireAgreement creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertiseCollaboration aims to develop novel, off-the-shelf, mRNA-based
2y agoCVACCureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSKACCESS NewswireSeasonal flu vaccine candidate boosted antibody titers at all dose levels and for all encoded seasonal influenza strains across younger and older adults Potentially differentiated, multivalent candidate encodes antigens
2y agoCVACCureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology PlatformACCESS NewswireHead-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profileMonovalent mRNA vaccine candidate, CV0601, encoding
2y agoCVACCureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SEACCESS NewswireValidity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SEDecision does not affect ongoing litigation in Germany regarding seven other intellectual property
2y agoCVACCureVac N.V. (CVAC) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
2y agoCVACCureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business UpdateACCESS NewswireCureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business UpdateEnrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on
3y agoCVACCureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSKACCESS NewswireCOVID-19 Phase 2 clinical trial fully enrolledStudy compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccineFirst participant dosed in seasonal flu Phase 2 part of combined Phase 1/2
3y agoCVACCureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad CoverageACCESS NewswirePhase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate mRNA constructs per candidateBest-performing candidate providing broad antigen coverage
3y agoCVACCureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business UpdateACCESS NewswireInitiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSKInitiated Phase 1 study of cancer
3y agoCVACCureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSKACCESS NewswirePhase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidatesVaccine candidates developed in collaboration with GSK within COVID-19 vaccine development